YU-YUN SHAOMING-CHIH HOANN-LII CHENGCHIH-HUNG HSU2020-02-192020-02-1920140929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904397747&doi=10.1016%2fj.jfma.2012.07.036&partnerID=40&md5=82bed44276b63612ef6e8999fe4ca0dehttps://scholars.lib.ntu.edu.tw/handle/123456789/461617[SDGs]SDG3alpha fetoprotein; bevacizumab; capecitabine; fluorodeoxyglucose f 18; alpha fetoprotein; angiogenesis inhibitor; antineoplastic antimetabolite; bevacizumab; capecitabine; adult; alpha fetoprotein blood level; antiangiogenic therapy; article; cancer combination chemotherapy; cancer surgery; cancer survival; case report; computer assisted tomography; disease free survival; female; follow up; human; human tissue; liver biopsy; liver cell carcinoma; liver resection; long term survival; lung metastasis; multimodality cancer therapy; phase 2 clinical trial (topic); positron emission tomography; splenectomy; systemic therapy; treatment response; tumor biopsy; young adult; Carcinoma, Hepatocellular; disease free survival; Liver Neoplasms; Lung Neoplasms; pathology; secondary; Splenic Neoplasms; Adult; alpha-Fetoproteins; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Splenic Neoplasms; Young AdultLong-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastasesjournal article10.1016/j.jfma.2012.07.036250377672-s2.0-84904397747